As a response to the growing data supporting the use of apoB as a CV risk-assessment tool, the latest ESC guidelines for the management of dyslipidemias recommend routine measurement of apoB for patients suffering from pathologies such as hypertriglyceridemia, diabetes, obesity, and metabolic syndrome [76]. This evidence concerns the gene APOB and obesity disorder.